(a) Systematic screening for active TB may be considered for geographically
defined subpopulations with extremely high levels of undetected TB (1%
prevalence or higher).
(b) Systematic screening for active TB may be considered also for other
subpopulations that have very poor access to health care, such as people
living in urban slums, homeless people, people living in remote areas with
poor access to health care, and other vulnerable or marginalized groups
including some indigenous populations, migrants and refugees.

In settings where the TB prevalence in the general
population is 100/100 000 population or higher, systematic screening for
active TB should be considered among people who are seeking health care or
who are in health care and who belong to selected risk groups.

Systematic screening for active TB should be considered
in people with an untreated fibrotic chest X-ray lesion.

Systematic screening for active TB should be considered
in prisons and other penitentiary institutions.

Current and former workers in workplaces with silica
exposure should be systematically screened for active TB.

People living with HIV should be systematically screened
for active TB at each visit to a health facility.

Household contacts and other close contacts should be
systematically screened for active TB.

The Expert Group recommended that the Genotype MTBDRsl assay cannot be used as a replacement
test for conventional phenotypic DST.

Children living with HIV who do not have poor weight gain, fever or current cough are unlikely to
have active TB.

Providing IPT to people living with HIV does not increase the risk of developing isoniazid-resistant
TB. Therefore, concerns regarding the development of INH resistance should not be a barrier to
providing IPT.